Talking About Tumors with Ryann and Ryan - A medical oncology podcast

05_02 Neuroendocrine Tumors

27 min · 3 de may de 2025
Portada del episodio 05_02 Neuroendocrine Tumors

Descripción

1. Nomenclature, unique considerations 2. Secretory Syndromes 3. Somatostatin directed therapy 4. Peptide Receptor Radionucleotide Therapy Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.  DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1–10 1.   Kunz PL  et al. Journal of Clinical Oncology. 2023;41(7):1359-1369. doi:10.1200/JCO.22.01013/ 2.  Strosberg JR et al. Lancet Oncol. 2021;22(12):1752-1763. doi:10.1016/S1470-2045(21)00572-6 3.  Strosberg J  et al. NEJM. 2017;376(2):125-135. doi:10.1056/NEJMOA1607427/ 4.  Caplin ME et al. NEJM. 2014;371(3):224-233. doi:10.1056/NEJMOA1316158/ 5.   Caplin ME et al. Endocrine. 2021;71(2):502-513. doi:10.1007/S12020-020-02475-6.  Neuroendocrine Tumor Guidelines, ESMO. Accessed May 1, 2025. https://www.esmo.org/guidelines/guidelines-by-topic/esmo-clinical-practice-guidelines-endocrine-and-neuroendocrine-cancers 7.   Pieterman CRC  , et al. J Neuroendocrinol. Published online January 1, 2024. doi:10.1111/JNE.13468 8.   NANETS. Accessed May 1, 2025. https://nanets.net/ 9.  Rinke A et al. Results of long-term survival. Neuroendocrinology. 2016;104(1):26-32. doi:10.1159/000443612, 10. Rinke A et al. J Clin Oncol. 2009;27(28):4656-4663. doi:10.1200/JCO.2009.22.8510,   Disclosures Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.  Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

Comentarios

0

Sé la primera persona en comentar

¡Regístrate ahora y únete a la comunidad de Talking About Tumors with Ryann and Ryan - A medical oncology podcast!

Prueba gratis

Empieza 7 días de prueba

$99 / mes después de la prueba. · Cancela cuando quieras

  • Podcasts solo en Podimo
  • 20 horas de audiolibros al mes
  • Podcast gratuitos

Todos los episodios

50 episodios

Portada del episodio 05_02 Neuroendocrine Tumors

05_02 Neuroendocrine Tumors

1. Nomenclature, unique considerations 2. Secretory Syndromes 3. Somatostatin directed therapy 4. Peptide Receptor Radionucleotide Therapy Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.  DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1–10 1.   Kunz PL  et al. Journal of Clinical Oncology. 2023;41(7):1359-1369. doi:10.1200/JCO.22.01013/ 2.  Strosberg JR et al. Lancet Oncol. 2021;22(12):1752-1763. doi:10.1016/S1470-2045(21)00572-6 3.  Strosberg J  et al. NEJM. 2017;376(2):125-135. doi:10.1056/NEJMOA1607427/ 4.  Caplin ME et al. NEJM. 2014;371(3):224-233. doi:10.1056/NEJMOA1316158/ 5.   Caplin ME et al. Endocrine. 2021;71(2):502-513. doi:10.1007/S12020-020-02475-6.  Neuroendocrine Tumor Guidelines, ESMO. Accessed May 1, 2025. https://www.esmo.org/guidelines/guidelines-by-topic/esmo-clinical-practice-guidelines-endocrine-and-neuroendocrine-cancers 7.   Pieterman CRC  , et al. J Neuroendocrinol. Published online January 1, 2024. doi:10.1111/JNE.13468 8.   NANETS. Accessed May 1, 2025. https://nanets.net/ 9.  Rinke A et al. Results of long-term survival. Neuroendocrinology. 2016;104(1):26-32. doi:10.1159/000443612, 10. Rinke A et al. J Clin Oncol. 2009;27(28):4656-4663. doi:10.1200/JCO.2009.22.8510,   Disclosures Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.  Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

3 de may de 202527 min
Portada del episodio 05_01 Hepatocellular carcinoma

05_01 Hepatocellular carcinoma

1. Etiologies and epidemiology 2. Staging and local/regional considerations 3. Systemic Therapy 4. Differences in immune checkpoint sensitivity by etiology Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.  DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1.           Finn RS, et al. Oncologist. 2022;27(12):E938-E948. doi:10.1093/ONCOLO/OYAC183 2.           Pfister D et al. Nature 2021 592:7854. 2021;592(7854):450-456. doi:10.1038/s41586-021-03362-0 3.           Zhu AX  et al. Lancet Oncol. 2019;20(2):282-296. doi:10.1016/S1470-2045(18)30937-9 4.           Abou-Alfa GK, et al. NEJM Evidence. 2022;1(8). doi:10.1056/EVIDOA2100070 5.           Kudo M, et al. Lancet. 2018;391(10126):1163-1173. doi:10.1016/S0140-6736(18)30207-1 7.           Llovet JM, et al. NEJM. 2008;359(4):378-390. doi:10.1056/NEJMOA0708857 8.           Reig M, et al.. J Hepatol. 2022;76(3):681-693. doi:10.1016/J.JHEP.2021.11.018 9.           Cheng AL et al.  J Hepatol. 2022;76(4):862-873. doi:10.1016/j.jhep.2021.11.030 10.        Finn RS et al. NEJM. 2020;382(20):1894-1905. doi:10.1056/NEJMOA1915745/ 11.        Rose S, et al. Lancet. 2024;404(10453):656-657. doi:10.1016/S0140-6736(24)00800-6   Disclosures Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.  Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

19 de dic de 202432 min
Portada del episodio 04_10 Testicular Cancer II

04_10 Testicular Cancer II

1. Stage II Disease 2. Overview of BEP, EP, VIP 3. Advanced, refractory disease 4. Survivorship considerations Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.  DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer.   1.          Pico JL et al. Ann Oncol. 2005;16(7):1152-1159. doi:10.1093/ANNONC/MDI228 2.          Adra N, et al. J Clin Oncol. 2017;35(10):1096-1102. doi:10.1200/JCO.2016.69.5395 3.          Nichols CR et al. J Clin Oncol. 1998;16(4):1287-1293. doi:10.1200/JCO.1998.16.4.1287 4.          de Wit R et al.. JCO. 1997;15(5):1837-1843. doi:10.1200/JCO.1997.15.5.1837 5.          Culine S, et al.  Ann Oncol. 2007;18(5):917-924. doi:10.1093/ANNONC/MDM062 6.          Lorch A, et al. Journal of Clinical Oncology. 2007;25(18_suppl):5086-5086. doi:10.1200/JCO.2007.25.18_SUPPL.5086 7.          Fung C, et al.. J Natl Compr Canc Netw. 2019;17(12):1557-1568. doi:10.6004/JNCCN.2019.7369   Disclosures Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.  Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

27 de oct de 202425 min
Portada del episodio 04_09 Testicular Cancer I

04_09 Testicular Cancer I

1. Background, work up 2. Staging of seminoma and NSGCT 3. Young Adult/Adolescent Oncology 4. Management of Stage I Disease   Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.  DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1.          Hiester A et al. Eur J Cancer. 2021;155:64-72. doi:10.1016/J.EJCA.2021.06.022 2.          Calaway AC et al. Eur Urol. 2019;76(5):607-609. doi:10.1016/j.eururo.2019.05.031 3.          Oliver RTD et al. J Clin Oncol. 2011;29(8):957-962. doi:10.1200/JCO.2009.26.4655 4.          Oliver RTD et al. Lancet. 2005;366(9482):293-300. doi:10.1016/S0140-6736(05)66984-X 5.          Joffe JK et al. JCO. 2022;40(22):2468-2478. doi:10.1200/JCO.21.01199/ 6.          Bhatia S et al.. J NCCN. 2023;21(8):851-880. doi:10.6004/JNCCN.2023.0040 7.          Stephenson A et al. J Urol. 2019;202(2):272-281. doi:10.1097/JU.0000000000000318     Disclosures Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.  Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

18 de sep de 202428 min
Portada del episodio 04_08 Metastatic Renal Cell Carcinoma

04_08 Metastatic Renal Cell Carcinoma

1. Historical Approach (cytoreduction, IFN-a, sunitinib 2. Prognostic risk scores 3. Evidence for modern doublet regimens 4. Later line therapy Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.  DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1. Flanigan RC et al.  J Urol.  2004;171(3):1071-6. doi:10.1097/01.ju0000110610.61545.ae 2. Bex A et al. JAMA Oncology. 2019;5(2):164-170.  doi:10.1001/jamaoncol.2018.5545 3. Mejean A et al. NEJM.  2018;379:417-427. doi:10.1056/NEJMoa1803675 4. Motzer RJ et al.  NEJM.  2007;356:115-124. doi:10.1056/NEJMoa065044 5. Rini BI et al.  NEJM.  2019;380:1116-1127. doi:10.1056/NEJMoa1816714 6. Rini BI et al. JCO.  2023;41(17 Supp).  doi:10.1200/JCO.2023.41.17_suppl.LBA4501 7. Kartolo et al. Urology. 2021;157:8-14. doi:10.1016/j.urology.2021.08.023 8. Motzer RJ et al. NEJM. 2018;378:1277-1290.  doi:10.1056/NEJMoa1712126 9. Motzer R et al.  NEJM.  2021;384:1289-1300.  doi:10.1056/NEJMoa2035716 10. Albiges L et al.  Ann Oncol.  2023;34(2 Supp):S1329-S1330.  doi:10.1016/j.annonc.2023.10.090 11. Jonasch E.  ASCO Annual Meeting presented May 31, 2024 in Chicago, IL   Disclosures Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.  Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

2 de ago de 202424 min